NCT00096603

Brief Summary

This is an open label, multicenter study designed to evaluate the safety and tolerability of efalizumab administered subcutaneously at weekly doses of 1.0 mg/kg in subjects with plaque psoriasis who previously participated in Study ACD2600g.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
450

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Oct 2002

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2002

Completed
1.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2004

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

November 12, 2004

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 15, 2004

Completed
Last Updated

March 20, 2014

Status Verified

March 1, 2014

First QC Date

November 12, 2004

Last Update Submit

March 19, 2014

Conditions

Psoriasis

Keywords

Moderate to severe plaque psoriasis

Interventions

Raptiva (efalizumab)DRUG

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Signed informed consent
  • Previous participation in Study ACD2600g
  • For women of childbearing potential, continued use of an acceptable method of contraception for the duration of the study

You may not qualify if:

  • Any medical condition that, in the judgment of the investigator, would jeopardize the subject's safety following exposure to Efalizumab

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Psoriasis

Interventions

efalizumab

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Study Design

Study Type
interventional
Phase
phase 3
Masking
NONE
Purpose
TREATMENT
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 12, 2004

First Posted

November 15, 2004

Study Start

October 1, 2002

Study Completion

July 1, 2004

Last Updated

March 20, 2014

Record last verified: 2014-03